Joachim Schofer1, Piotr Musiałek2, Klaudija Bijuklic3, Ralf Kolvenbach4, Mariusz Trystula2, Zbigniew Siudak5, Horst Sievert6. 1. Medical Care Center, Hamburg University Cardiovascular Center, Hamburg, Germany. Electronic address: Schofer@herz-hh.de. 2. Jagiellonian University Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow, Poland. 3. Medical Care Center, Hamburg University Cardiovascular Center, Hamburg, Germany. 4. Augusta Hospital, Dusseldorf, Germany. 5. Jagiellonian University Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow, Poland; Krakow Cardiovascular Research Institute, Krakow, Poland. 6. CardioVascular Center, Frankfurt, Germany.
Abstract
OBJECTIVES: This study sought to evaluate the feasibility of the CGuard Carotid Embolic Protective Stent system-a novel thin strut nitinol stent combined with a polyethylene terephthalate mesh covering designed to prevent embolic events from the target lesion in the treatment of carotid artery lesions in consecutive patients suitable for carotid artery stenting. BACKGROUND: The risk of cerebral embolization persists throughout the carotid artery stenting procedure and remains during the stent healing period. METHODS: A total of 30 consecutive patients (age 71.6 ± 7.6 years, 63% male) meeting the conventional carotid artery stenting inclusion criteria were enrolled in 4 centers in Germany and Poland. RESULTS: The primary combined endpoint was the procedure success of the CGuard system and the number and volume of new lesions on the ipsilateral side assessed by diffusion-weighted magnetic resonance imaging at 48 h post-procedure and at 30 days. The secondary endpoint was 30-day major adverse cardiac or cerebrovascular events (death, stroke, or myocardial infarction). Protection devices were used in all procedures. Procedure success was 100%, with 0% procedural complications. The 30-day major adverse cardiac or cerebrovascular events rate was 0%. New ipsilateral ischemic lesions at 48 h occurred in 37.0% of patients and the average lesion volume was 0.039 ± 0.08 cm(3). The 30-day diffusion-weighted magnetic resonance imaging showed complete resolution of all but 1 periprocedural lesion and only 1 new minor (0.116 cm(3)) lesion in relation to the 48-h scan. CONCLUSIONS: The use of the CGuard system in patients undergoing carotid artery stenting is feasible. In addition, the benefit of using CGuard may extend throughout the stent healing period.
OBJECTIVES: This study sought to evaluate the feasibility of the CGuard Carotid Embolic Protective Stent system-a novel thin strut nitinol stent combined with a polyethylene terephthalate mesh covering designed to prevent embolic events from the target lesion in the treatment of carotid artery lesions in consecutive patients suitable for carotid artery stenting. BACKGROUND: The risk of cerebral embolization persists throughout the carotid artery stenting procedure and remains during the stent healing period. METHODS: A total of 30 consecutive patients (age 71.6 ± 7.6 years, 63% male) meeting the conventional carotid artery stenting inclusion criteria were enrolled in 4 centers in Germany and Poland. RESULTS: The primary combined endpoint was the procedure success of the CGuard system and the number and volume of new lesions on the ipsilateral side assessed by diffusion-weighted magnetic resonance imaging at 48 h post-procedure and at 30 days. The secondary endpoint was 30-day major adverse cardiac or cerebrovascular events (death, stroke, or myocardial infarction). Protection devices were used in all procedures. Procedure success was 100%, with 0% procedural complications. The 30-day major adverse cardiac or cerebrovascular events rate was 0%. New ipsilateral ischemic lesions at 48 h occurred in 37.0% of patients and the average lesion volume was 0.039 ± 0.08 cm(3). The 30-day diffusion-weighted magnetic resonance imaging showed complete resolution of all but 1 periprocedural lesion and only 1 new minor (0.116 cm(3)) lesion in relation to the 48-h scan. CONCLUSIONS: The use of the CGuard system in patients undergoing carotid artery stenting is feasible. In addition, the benefit of using CGuard may extend throughout the stent healing period.
Authors: Thomas G Brott; George Howard; Gary S Roubin; James F Meschia; Ariane Mackey; William Brooks; Wesley S Moore; Michael D Hill; Vito A Mantese; Wayne M Clark; Carlos H Timaran; Donald Heck; Pierre P Leimgruber; Alice J Sheffet; Virginia J Howard; Seemant Chaturvedi; Brajesh K Lal; Jenifer H Voeks; Robert W Hobson Journal: N Engl J Med Date: 2016-02-18 Impact factor: 91.245
Authors: Ján Sýkora; Kamil Zeleňák; Martin Vorčák; Martin Števík; Martina Sýkorová; Jozef Sivák; Marek Rovňák; Jana Zapletalová; Juraj Mužík; Igor Šinák; Egon Kurča; Lukas Meyer; Jens Fiehler Journal: Cardiovasc Intervent Radiol Date: 2022-07-07 Impact factor: 2.797
Authors: Roman Machnik; Piotr Paluszek; Łukasz Tekieli; Karolina Dzierwa; Damian Maciejewski; Mariusz Trystuła; Andrzej Brzychczy; Krzysztof Banaszkiewicz; Robert Musiał; Piotr Pieniążek Journal: Postepy Kardiol Interwencyjnej Date: 2017-05-30 Impact factor: 1.426
Authors: Piotr Pieniążek; Przemysław Nowakowski; Krzysztof Ziaja; Adam Kobayashi; Wojciech Uchto; Jakub Sulżenko; Roman Machnik; Łukasz Tekieli; Dariusz Stańczyk; Krzysztof Plens; Wojciech Zasada; Artur Dziewierz; Damian Ziaja Journal: Postepy Kardiol Interwencyjnej Date: 2019-12-31 Impact factor: 1.426